BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30694321)

  • 1. Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes.
    Luo J; Khan NF; Manetti T; Rose J; Kaloghlian A; Gadhe B; Jain SH; Gagne JJ; Kesselheim AS
    JAMA; 2019 Jan; 321(4):374-384. PubMed ID: 30694321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
    Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
    JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sociodemographic, Clinical, and Treatment-Related Factors Associated With Hyperglycemic Crises Among Adults With Type 1 or Type 2 Diabetes in the US From 2014 to 2020.
    McCoy RG; Galindo RJ; Swarna KS; Van Houten HK; O'Connor PJ; Umpierrez GE; Shah ND
    JAMA Netw Open; 2021 Sep; 4(9):e2123471. PubMed ID: 34468753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
    McCoy RG; Lipska KJ; Van Houten HK; Shah ND
    JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Targeted Insulin-Adherence Interventions for Glycemic Control Using Predictive Analytics Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Lauffenburger JC; Lewey J; Jan S; Makanji S; Ferro CA; Krumme AA; Lee J; Ghazinouri R; Haff N; Choudhry NK
    JAMA Netw Open; 2019 Mar; 2(3):e190657. PubMed ID: 30874782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a program to improve diabetes care through intensified care management activities and diabetes medication copayment reduction.
    Kogut SJ; Johnson S; Higgins T; Quilliam B
    J Manag Care Pharm; 2012 May; 18(4):297-310. PubMed ID: 22548690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database.
    Bae JP; Duan R; Fu H; Hoogwerf BJ
    Clin Ther; 2017 Sep; 39(9):1790-1798.e7. PubMed ID: 28781218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
    JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Vanderheiden A; Harrison L; Warshauer J; Li X; Adams-Huet B; Lingvay I
    JAMA Intern Med; 2016 Jul; 176(7):939-47. PubMed ID: 27273731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.
    Bieszk N; Reynolds SL; Wei W; Davis C; Kamble P; Uribe C
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1028-38. PubMed ID: 27579824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes.
    Lauffenburger JC; Lewey J; Jan S; Lee J; Ghazinouri R; Choudhry NK
    JAMA Netw Open; 2020 Jan; 3(1):e1919645. PubMed ID: 31968115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Telemedicine Use and Glycemic Outcomes of Endocrinology Care for Patients With Type 2 Diabetes.
    Zupa MF; Vimalananda VG; Rothenberger SD; Lin JY; Ng JM; McCoy RG; Rosland AM
    JAMA Netw Open; 2023 Dec; 6(12):e2346305. PubMed ID: 38055278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemia observed during continuous glucose monitoring in patients with type 2 diabetes mellitus treated by subcutaneous insulin injection.
    Ito H; Abe M; Shinozaki M; Oshikiri K; Yamashita H; Nakashima M; Takaki A; Yukawa C; Furusho M; Antoku S; Mifune M; Togane M
    Diabetes Technol Ther; 2013 Jul; 15(7):586-90. PubMed ID: 23578166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins.
    Neugebauer R; Schroeder EB; Reynolds K; Schmittdiel JA; Loes L; Dyer W; Desai JR; Vazquez-Benitez G; Ho PM; Anderson JP; Pimentel N; O'Connor PJ
    JAMA Netw Open; 2020 Jan; 3(1):e1918554. PubMed ID: 31977057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.